Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Stability of intraindividual variability as a marker of neurologic dysfunction in relapsing remitting multiple sclerosis.
Antibody-Mediated Inhibition of TNFR1 Attenuates Disease in a Mouse Model of Multiple Sclerosis.
Isolated anti-β2-glycoprotein I antibodies in neurology: a frontier syndrome between multiple sclerosis and antiphospholipid syndrome?
Tissue structure and inflammatory processes shape viscoelastic properties of the mouse brain.
Effects of isoxazolo-pyridinone 7e, a potent activator of the nurr1 signaling pathway, on experimental autoimmune encephalomyelitis in mice.
Spanish consensus on the use of natalizumab (Tysabri(®))-2013.
Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells.
Demyelinating disease: NMO spectrum disorders: clinical or molecular classification?
Evaluating change in mobility in people with multiple sclerosis: relative responsiveness of four clinical measures.
Characterization of dose-response for count data using a generalized MCP-Mod approach in an adaptive dose-ranging trial.
Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.
Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?
The need for randomization in animal trials: an overview of systematic reviews.
Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study.
Nitrous Oxide Abuse and Vitamin B12 Action in a 20-Year-Old Woman: A Case Report.
Ubiquitous Over-Expression of Chromatin Remodeling Factor SRG3 Ameliorates the T Cell-Mediated Exacerbation of EAE by Modulating the Phenotypes of both Dendritic Cells and Macrophages.
How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?
Ocular and cervical vestibular evoked myogenic potentials in patients with multiple sclerosis.
Effects of Brain-Derived IL-2 Deficiency and the Development of Autoimmunity on Spatial Learning and Fear Conditioning.
Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders?
Should Plasma Exchange Be Offered to Patients With Multiple Sclerosis-Associated Optic Neuritis?
A spectrum of inflammation and demyelinization in acute disseminated encephalomyelitis (ADEM) of children.
Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.
Use of botulinum toxin in individuals with neurogenic detrusor overactivity: State of the art review.
Innate IFN-γ promotes development of experimental autoimmune encephalomyelitis: A role for NK cells and M1 macrophages.
Pages
« first
‹ previous
…
487
488
489
490
491
492
493
494
495
…
next ›
last »